Share

March 03, 2015; 84 (9) Editorial

Multiple sclerosis, immunomodulation, and immunizations

Balancing the benefits

Myla D. Goldman, Robert T. Naismith
First published January 30, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001319
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
300

Share

Article Information

vol. 84 no. 9 864-865
DOI: 
https://doi.org/10.1212/WNL.0000000000001319
PubMed: 
25636716
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published January 30, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Myla D. Goldman, MD, MSc and
    2. Robert T. Naismith, MD
  1. Myla D. Goldman, MD, MSc and
    2. Scientific Advisory Boards:

    1. Novartis Pharmeceuticals Biogen, IDEC.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 10/2012 - present: Associate editor, Therapeutic Advances in Neurological Disorders 6/2008 ? 3/2012 Member, Editorial Board, International Journal of MS Care

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Concert Pharmaceuticals Questcor

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Acroda Therapeutics: Travel and Lodging Reimbursement

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Institutional Contracts *Biogen, Idec *Novartis Pharm.

    Research Support, Government Entities:

    1. Title: K-23 Career Development Award: Validation of a Motor Fatigue measure in Multiple Sclerosis Agency: NINDS Period: Jan 2010 - Dec 2015 Role: Principal Investigator Title: Personalized Signal Processing for Early Diagnosis of Mobility Impairment Agency: National Science Foundation Period: 2012-2015 Role: Advisor

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. ziMS Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert T. Naismith, MD
    3. Scientific Advisory Boards:

    1. 1) Acorda Therapeutics

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Bayer Healthcare, speaker honoraria and travel (commercial) 3) Biogen IDEC, speaker honoraria and travel (commercial) 4) Genzyme Corporation, speaker honoraria and travel (commercial) 5) National MS Society, speaker honoraria and travel (not- for profit) 6) Consortium MS Centers, speaker honoraria and travel (not-for-profit) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Questcor Therapeutics, consulting honoraria and travel (commercial) 9) Genentech, consulting honoraria (commercial) 10) Novartis, consulting honoraria and travel (commercial)

    Editorial Boards:

    1. Journal Watch 2010-present, Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1) Acorda Therapeutics (commercial) 2) Bayer Healthcare (commercial) 3) Biogen Idec (commercial) 4) Genzyme Corporation (commercial)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Acorda Therapeutics - Washington University site PI for national Fampridine SR clinical trial, 2004-2010. Dalfampridine for vision after optic neuritis in MS, 2011- present.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.
  1. Correspondence to Dr. Goldman: mdg3n{at}virginia.edu
View Full Text

Article usage

Article usage: January 2015 to July 2022

AbstractFullPdfSource
Jan 201586014Highwire
Feb 2015277160Highwire
Mar 201567852103Highwire
Apr 201536412Highwire
May 20153925Highwire
Jun 20154354Highwire
Jul 2015491111Highwire
Aug 20154277Highwire
Sep 2015471310Highwire
Oct 201544104Highwire
Nov 20151733Highwire
Dec 20151820Highwire
Jan 20161852Highwire
Feb 20162423Highwire
Mar 20161923Highwire
Apr 2016422Highwire
May 2016511Highwire
Jun 20161210Highwire
Jul 20162032Highwire
Aug 20161222Highwire
Sep 20161210Highwire
Oct 20162701Highwire
Nov 20161510Highwire
Dec 20161101Highwire
Jan 20172726Highwire
Feb 2017811Highwire
Mar 2017511Highwire
Apr 20171511Highwire
May 20171000Highwire
Jun 20171143Highwire
Jul 2017310Highwire
Aug 2017710Highwire
Sep 2017932Highwire
Oct 20171100Highwire
Nov 2017700Highwire
Dec 20171400Highwire
Jan 20181211Highwire
Feb 20181243Highwire
Mar 20181922Highwire
Apr 20181044Highwire
May 2018711Highwire
Jun 20181233Highwire
Jul 2018743Highwire
Aug 2018600Highwire
Sep 2018600Highwire
Oct 20181001Highwire
Nov 2018531Highwire
Dec 20181410Highwire
Jan 2019800Highwire
Feb 2019821Highwire
Mar 20197822Highwire
Apr 20191830Highwire
May 20191510Highwire
Jun 2019300Highwire
Jul 2019910Highwire
Aug 20191111Highwire
Sep 20191000Highwire
Oct 20192312Highwire
Nov 20191300Highwire
Dec 2019610Highwire
Jan 20201000Highwire
Feb 2020800Highwire
Mar 2020700Highwire
Apr 2020710Highwire
May 2020442Highwire
Jun 2020400Highwire
Jul 2020900Highwire
Aug 20201300Highwire
Sep 20201610Highwire
Oct 20201611Highwire
Nov 20201341Highwire
Dec 2020610Highwire
Jan 20211922Highwire
Feb 20211811Highwire
Mar 20211531Highwire
Apr 2021400Highwire
May 20211810Highwire
Jun 2021722Highwire
Jul 20211100Highwire
Aug 2021900Highwire
Sep 2021900Highwire
Oct 20211800Highwire
Nov 20211300Highwire
Dec 20211100Highwire
Jan 2022510Highwire
Feb 20221700Highwire
Mar 2022800Highwire
Apr 20221100Highwire
May 2022900Highwire
Jun 2022800Highwire
Jul 2022201Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me